Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Completed × lortalamine × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Disease 1

Interventions

Cyclophosphamide 294 Cisplatin 291 Radiotherapy 253 Paclitaxel 253 Fluorouracil 233 Docetaxel 230 Carboplatin 228 Doxorubicin 210 Dexamethasone 163 Gemcitabine 154 Vincristine 140 Etoposide 131 Leucovorin 130 Capecitabine 129 Bevacizumab 126 Prednisone 123 Rituximab 117 Methotrexate 116 Cytarabine 107 Trastuzumab 98 Filgrastim 98 Oxaliplatin 95 pembrolizumab 77 Pemetrexed 70 Epirubicin 70 Tamoxifen 69 Drug Therapy 68 Irinotecan 64 Granulocyte Colony-Stimulating Factor 59 Nivolumab 56

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡